Retrospective analysis reveals high prevalence of HCV genotype 3a in pulmonary TB patients, highlighting the need for improved antiviral therapy access.
Key Points
Fibrosis and metabolic disorders are common in pulmonary TB patients coinfected with HCV, especially genotype 3a.
Social status significantly affects access to antiviral therapy, with many patients being unemployed or socially vulnerable.
Bacteriologically confirmed TB predominates, emphasizing the importance of timely diagnosis and treatment planning.
Early detection and consistent monitoring are crucial for treatment success among coinfected patients.